Compare Stocks

Date Range: 

 Cardiff OncologyOutlook TherapeuticsSurface OncologyCodiak BioSciencesEiger BioPharmaceuticals
SymbolNASDAQ:CRDFNASDAQ:OTLKNASDAQ:SURFNASDAQ:CDAKNASDAQ:EIGR
Price Information
Current Price$10.04$2.30$7.25$20.08$9.23
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.91.31.42.01.8
Analysis Score3.53.53.33.53.5
Community Score3.12.82.64.02.9
Dividend Score0.00.00.00.00.0
Ownership Score2.50.00.81.72.5
Earnings & Valuation Score0.60.00.00.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$23.75$6.33$13.60$30.00$25.00
% Upside from Price Target136.55% upside175.36% upside87.59% upside49.40% upside170.86% upside
Trade Information
Market Cap$377.02 million$399.29 million$314.82 million$441.64 million$313.37 million
Beta1.80.462.09N/A1.54
Average Volume1,549,6843,794,3081,479,600217,782252,628
Sales & Book Value
Annual Revenue$250,000.00$8.15 million$15.36 millionN/AN/A
Price / Sales1,508.0948.9920.50N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.94 per share$0.02 per share$2.03 per shareN/A$2.31 per share
Price / Book10.68115.003.57N/AN/A
Profitability
Net Income$-16,410,000.00$-35,240,000.00$-54,790,000.00N/A$-70,250,000.00
EPS($2.80)($0.67)($1.97)N/A($3.08)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-4,990.52%N/AN/AN/AN/A
Return on Equity (ROE)-95.03%N/A-29.77%N/A-100.60%
Return on Assets (ROA)-71.77%-148.04%-17.05%N/A-57.76%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.33%0.17%N/A0.27%
Current Ratio7.02%1.13%7.94%1.52%6.23%
Quick Ratio7.02%1.13%7.94%1.52%6.23%
Ownership Information
Institutional Ownership Percentage52.97%3.04%51.97%N/A68.77%
Insider Ownership Percentage0.60%4.00%35.00%N/A5.80%
Miscellaneous
Employees1185110528
Shares Outstanding37.55 million173.61 million43.42 million21.99 million33.95 million
Next Earnings Date5/27/2021 (Estimated)5/21/2021 (Estimated)5/11/2021 (Estimated)6/16/2021 (Estimated)5/6/2021 (Confirmed)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Eiger to add Peginterferon Lambda to Covid-19 trial in BrazilEiger to add Peginterferon Lambda to Covid-19 trial in Brazil
clinicaltrialsarena.com - May 4 at 9:59 AM
Eiger BioPharmaceuticals Announces Peginterferon Lambda to be Added to Multi-Center Phase 3 TOGETHER COVID-19 Study in BrazilEiger BioPharmaceuticals Announces Peginterferon Lambda to be Added to Multi-Center Phase 3 TOGETHER COVID-19 Study in Brazil
finance.yahoo.com - May 3 at 8:48 AM
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Expected to Announce Quarterly Sales of $970,000.00Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Expected to Announce Quarterly Sales of $970,000.00
americanbankingnews.com - May 1 at 3:34 AM
Eiger BioPharmaceuticals (EIGR) Set to Announce Earnings on ThursdayEiger BioPharmaceuticals (EIGR) Set to Announce Earnings on Thursday
americanbankingnews.com - April 30 at 9:46 AM
Eiger BioPharmaceuticals (EIGR) Scheduled to Post Earnings on ThursdayEiger BioPharmaceuticals (EIGR) Scheduled to Post Earnings on Thursday
americanbankingnews.com - April 30 at 9:46 AM
Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2021 Financial Results and Business Update on Thursday, May 6, 2021Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2021 Financial Results and Business Update on Thursday, May 6, 2021
finance.yahoo.com - April 29 at 9:00 AM
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Expected to Announce Earnings of -$0.51 Per ShareEiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Expected to Announce Earnings of -$0.51 Per Share
americanbankingnews.com - April 29 at 8:42 AM
Preview: Taking on the EigerPreview: Taking on the Eiger
cbsnews.com - April 28 at 12:13 AM
Eiger BioPharmaceuticals Appoints Commercial Expert and Industry Veteran Kim Sablich to its Board of DirectorsEiger BioPharmaceuticals Appoints Commercial Expert and Industry Veteran Kim Sablich to its Board of Directors
finance.yahoo.com - April 22 at 12:32 PM
Wednesday 4/14 Insider Buying Report: RAPT, EIGRWednesday 4/14 Insider Buying Report: RAPT, EIGR
nasdaq.com - April 15 at 7:58 AM
Thomas John Dietz Acquires 2,500 Shares of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) StockThomas John Dietz Acquires 2,500 Shares of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Stock
americanbankingnews.com - April 12 at 7:38 PM
Zacks: Brokerages Expect Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Will Post Earnings of -$0.51 Per ShareZacks: Brokerages Expect Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Will Post Earnings of -$0.51 Per Share
americanbankingnews.com - April 12 at 10:28 AM
Drosophila TNFRs Grindelwald and Wengen bind Eiger with different affinities and promote distinct cellular functionsDrosophila TNFRs Grindelwald and Wengen bind Eiger with different affinities and promote distinct cellular functions
nature.com - April 7 at 7:52 AM
Are Insiders Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Stock?Are Insiders Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Stock?
finance.yahoo.com - March 24 at 1:22 PM
Eiger BioPharma: Q4 Earnings SnapshotEiger BioPharma: Q4 Earnings Snapshot
apnews.com - March 9 at 7:52 PM
Eiger BioPharma: Q4 Earnings Snapshot | Raleigh News & ObserverEiger BioPharma: Q4 Earnings Snapshot | Raleigh News & Observer
newsobserver.com - March 9 at 7:52 PM
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdateEiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
finance.yahoo.com - March 9 at 7:52 PM
Eiger BioPharmaceuticals (EIGR) Reports Q4 Loss, Lags Revenue EstimatesEiger BioPharmaceuticals (EIGR) Reports Q4 Loss, Lags Revenue Estimates
finance.yahoo.com - March 9 at 7:52 PM
Deadly Tragedy Took Place In ‘The Eiger Sanction,’ One Of Clint Eastwood’s Earliest FilmsDeadly Tragedy Took Place In ‘The Eiger Sanction,’ One Of Clint Eastwood’s Earliest Films
doyouremember.com - March 9 at 9:51 AM
Eiger Bios Avexitide Shows Reduced Rates Of Hypoglycemia, Rescue In Outpatient SettingEiger Bio's Avexitide Shows Reduced Rates Of Hypoglycemia, Rescue In Outpatient Setting
finance.yahoo.com - February 23 at 5:59 PM
Eiger Announces Publication of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia in Journal of Clinical Endocrinology & MetabolismEiger Announces Publication of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia in Journal of Clinical Endocrinology & Metabolism
finance.yahoo.com - February 23 at 12:59 PM
Mammut Eiger Extreme: crucial athlete test at Lake BaikalMammut Eiger Extreme: crucial athlete test at Lake Baikal
ispo.com - January 27 at 4:18 AM
Eiger BioPharmaceuticals Announces US Commercial Availability Of Zokinvy For Progeria And Processing-Deficient Progeroid LaminopathiesEiger BioPharmaceuticals Announces US Commercial Availability Of Zokinvy For Progeria And Processing-Deficient Progeroid Laminopathies
benzinga.com - January 26 at 10:23 PM
Eiger Extreme in detailEiger Extreme in detail
ispo.com - January 26 at 5:22 PM
Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy™ (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid LaminopathiesEiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy™ (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies
finance.yahoo.com - January 25 at 11:17 AM
DateCompanyBrokerageAction
1/19/2021Cardiff OncologyHC WainwrightReiterated Rating
10/21/2020Cardiff OncologyMaxim GroupBoost Price Target
10/8/2020Cardiff OncologyPiper SandlerInitiated Coverage
5/29/2020Cardiff OncologyNoble FinancialReiterated Rating
2/17/2021Outlook TherapeuticsLADENBURG THALM/SH SHReiterated Rating
8/18/2020Outlook TherapeuticsOppenheimerLower Price Target
5/5/2020Outlook TherapeuticsBrookline Capital ManagementInitiated Coverage
5/16/2019Outlook TherapeuticsCIBCInitiated Coverage
4/22/2019Outlook TherapeuticsAscendiant Capital MarketsInitiated Coverage
4/11/2021Surface OncologyJonestradingReiterated Rating
3/22/2021Surface OncologyRobert W. BairdReiterated Rating
8/27/2020Surface OncologyWedbushInitiated Coverage
6/11/2020Surface OncologyCowenReiterated Rating
6/8/2020Surface OncologyEvercore ISIReiterated Rating
5/14/2018Surface OncologyThe Goldman Sachs GroupInitiated Coverage
4/16/2021Codiak BioSciencesWilliam BlairReiterated Rating
12/16/2019Eiger BioPharmaceuticalsGilford SecuritiesInitiated Coverage
6/26/2019Eiger BioPharmaceuticalsKeyCorpInitiated Coverage
6/26/2019Eiger BioPharmaceuticalsCitigroupInitiated Coverage
12/19/2018Eiger BioPharmaceuticalsBTIG ResearchBoost Price Target
(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.